Skip to content
The Nexus
HEALTHJul 8 · 07:41 UTCBLOOMBERGSatviki Sanjay

India Fat-Loss Drug Sales Slow After Early Spike From Generics

Sales of fat-loss drugs in India have slowed after an initial surge driven by generic versions of semaglutide-based medications. Semaglutide is the active ingredient in Novo Nordisk’s Ozempic and Wegovy.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
IndiaplacesemaglutidetopicNovo NordiskorganizationOzempictopicWegovytopicGenericstopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting